Cargando…
Molecularly profiled trials: toward a framework of actions for the “nil actionables”
The sequencing of tumour or blood samples is increasingly used to stratify patients into clinical trials of molecularly targeted agents, and this approach has frequently demonstrated clinical benefit for those who are deemed eligible. But what of those who have no clear and evident molecular driver?...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150144/ https://www.ncbi.nlm.nih.gov/pubmed/34040178 http://dx.doi.org/10.1038/s41416-021-01423-9 |